Abstract
Objective
During the past 30 years, various cardiovascular drugs have been implicated as causes of depression or suicide. Although the evidence for causal relationships has generally been conflicting, both β-blockers and angiotensin-converting-enzyme inhibitors (ACE-inhibitors) have been related to depression. Lipid-lowering therapies and calcium-channel blockers have also been linked to an increased risk of suicide. In this study, we investigated the possible association between the use of cardiovascular drugs and suicide using population-based register data.
Methods
We performed a nested case-control study in the county of Funen, Denmark, that consisted of 743 cases of completed suicide identified in a Death Registry for the period 1991–1998 and 14,860 age- and sex-matched controls. Information on previous drug use was retrieved from prescription data and the association between suicide and use of cardiovascular drugs was analysed by conditional logistic regression. Previous exposures to other drugs were used as proxies for potential confounding co-morbidities, including the use of psychotropic drugs to indicate psychiatric illness.
Results
The risk of suicide was not associated with current exposure to lipid-lowering drugs [odds ratio (OR): 1.21; 95% confidence interval (95% CI): 0.45–3.28), calcium-channel blockers (OR: 0.96; 95% CI: 0.63–1.48), β-blockers (OR: 0.76; 95% CI: 0.47–1.25) or ACE-inhibitors (OR: 1.11; 95% CI: 0.68–1.83). Suicide risk was associated with current angiotensin-receptor antagonist use (OR: 3.52; 95% CI: 1.33–9.30) based on five of the cases exposed.
Conclusion
With the exception of the imprecise risk associated with current use of angiotensin-receptor antagonists, the results from our study do not support the hypothesis that other cardiovascular drugs are associated with an increased the risk of suicide.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Jepsen P, Johnsen SP, Sorensen HT (2003) Risk of suicide in users of cardiovascular drugs: a review of the epidemiological evidence. Am J Cardiovasc Drugs 3:163–167
Patten SB (1990) Propranolol and depression: evidence from the antihypertensive trials. Can J Psychiatry 35:257–259
Rathmann W, Haastert B, Roseman JM, Giani G (1999) Cardiovascular drug prescriptions and risk of depression in diabetic patients. J Clin Epidemiol 11:1103–1109
Hallas J (1996) Evidence of depression provoked by cardiovascular medication: a prescription sequence symmetry analysis. Epidemiology 7:478–484
Patten SB, Williams JV, Love EJ (1996) Case-control studies of cardiovascular medications as risk factors for clinically diagnosed depressive disorders in a hospitalized population. Can J Psychiatry 41:469–476
Muldoon MF, Manuck SB, Matthews KA (1990) Lowering cholesterol concentrations and mortality: a quantitative review of primary prevention trials. Br Med J 301:309–314
Lindberg G, Bingefors K, Ranstam J, Rastam L, Melander A (1998) Use of calcium channel blockers and risk of suicide: ecological findings confirmed in population based cohort study. Br Med J 7:741–745
Brunner J, Parhofer KG, Schwandt P, Bronisch T (2002) Cholesterol, essential fatty acids, and suicide. Pharmacopsychiatry 35:1–5
Gasse C, Derby LE, Vasilakis C, Jick H (2000) Risk of suicide among users of calcium channel blockers: population based, nested case-control study. Br Med J 320:1251
Sorensen HT, Mellemkjaer L, Olsen JH (2001) Risk of suicide in users of beta-adrenoceptor blockers, calcium channel blockers and angiotensin converting enzyme inhibitors. Br J Clin Pharmacol 52:313–318
Yang CC, Jick SS, Jick H (2003) Lipid-lowering drugs and the risk of depression and suicidal behavior. Arch Intern Med 163:1926–1932
Andersen UA, Andersen M, Rosholm JU, Gram LF (2000) Contacts to the health care system prior to suicide: a comprehensive analysis using registers for general and psychiatric hospital admissions, contacts to general practitioners and practising specialists and drug prescriptions. Acta Psychiatr Scand 102:126–134
Andersen UA, Andersen M, Rosholm JU, Gram LF (2001) Psychopharmacological treatment and psychiatric morbidity in 390 cases of suicide with special focus on affective disorders. Acta Psychiatr Scand 104:458–465
Young-Xu Y, Chan KA, Liao JK, Ravid S, Blatt CM (2003) Long-term statin use and psychological well-being. J Am Coll Cardiol 42:690–697
Bergman U, Isacsson G (1998) Use of calcium channel blockers and risk of suicide. Independent studies are needed before causality is established. Br Med J 317:1076
Chen YT, Makuch RW (1998) Use of calcium channel blockers and risk of suicide. Prescriptions for particular drug are influenced by numerous factors. Br Med J 317:1077
Wiholm BE, Sundstrom A, Alfredsson L (1998) Use of calcium channel blockers and risk of suicide. Drug prescriptions over longer period should have been followed up. Br Med J 317:1076–1077
Conant J, Engler R, Janowsky D, Maisel A, Gilpin E, LeWinter M (1989) Central nervous system side effects of beta-adrenergic blocking agents with high and low lipid solubility. J Cardiovasc Pharmacol 13:656–661
Ullrich H, Passenberg P, Agelink MW (2003) Episodes of depression with attempted suicide after taking valsartan with hydrochlorothiazide. Dtsch Med Wochenschr 128:2534–2536
Gard PR, Mandy A, Sutcliffe MA (1999) Evidence of a possible role of altered angiotensin function in the treatment, but not etiology, of depression. Biol Psychiatry 45:1030–1034
Golomb BA, Kane T, Dimsdale JE (2004) Severe irritability associated with statin cholesterol-lowering drugs. Q J Med 97:229–235
Acknowledgements
The study was supported by the Danish Medical Research Council (grant no. 22-02-0395).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Callréus, T., Agerskov Andersen, U., Hallas, J. et al. Cardiovascular drugs and the risk of suicide: a nested case-control study. Eur J Clin Pharmacol 63, 591–596 (2007). https://doi.org/10.1007/s00228-007-0293-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00228-007-0293-5